TG Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on TG Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how TG Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with TG Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
TG Therapeutics Inc (TG Therapeutics) is a biopharmaceutical company which acquires, develops, and commercializes pharmaceutical products for the treatment of B-cell malignancies and various autoimmune diseases. Its marketed product Briumvi (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved for treating relapsing forms of multiple sclerosis. TG Therapeutics serves adult patients with multiple sclerosis, providing treatments that address clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The company also evaluates products and technologies for in-licensing, partnership, acquisition, and investment. The company has operations in the US, Australia, and the UK. TG Therapeutics is headquartered in Morrisville, North Carolina, the US.
Headquarters
United States of America
Address
3020 Carrington Mill Blvd., Suite 475, Morrisville, North Carolina, 27560-5435
Website
www.tgtherapeutics.com
Telephone
1 302 6587581
No of Employees
399
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
TGTX (NASD)
Revenue (2025)
$616.3M
87.3%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
1812.4%
(2025 vs 2024)
Market Cap*
$8.2B
Net Profit Margin (2025)
XYZ
920.5%
(2025 vs 2024)
* As of and is in US$
TG Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Briumvi (ublituximab- xiiy): Relapsing Forms of Multiple Sclerosis | Briumvi |
| Pipeline | TG Patient Support |
| Ublituximab IV: Relapsing Forms of Multiple Sclerosis (RMS) | Next In MS |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | TG Therapeutics Inc | Roche Holding AG | Novartis AG | Acorda Therapeutics Inc | Infinity Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | Switzerland | United States of America | United States of America |
| City | Morrisville | Basel | Basel | Pearl River | Cambridge |
| State/Province | North Carolina | Basel-Stadt | Basel-Stadt | New York | Massachusetts |
| No. of Employees | 399 | 112,774 | 75,267 | 102 | 30 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael S. Weiss | Chairman; Chief Executive Officer; President | Executive Board | 2011 | 60 |
| Sean A. Power | Chief Financial Officer | Senior Management | 2011 | 44 |
| Adam Waldman | Chief Commercial Officer | Senior Management | 2018 | - |
| Kenneth Hoberman | Director | Non Executive Board | 2014 | 60 |
| Yann Echelard, Ph.D. | Director | Non Executive Board | 2012 | 62 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer